# The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

> **NCT03129698** · PHASE2 · UNKNOWN · sponsor: **Junling Li** · enrollment: 52 (estimated)

## Conditions studied

- Apatinib in Maintenance Treatment

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03129698
- **Lead sponsor:** Junling Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-11
- **Primary completion:** 2019-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129698, "The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03129698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*